| GNA Biosolutions–GreyBird Ventures: investment, 201908 financing round Series C totalling $13.5m incl new investor GreyBird Ventures |
2019-08-05 |
| GNA Biosolutions–Mey Capital Matrix: investment, 201908 financing round Series C totalling $13.5m incl existing investor Mey Capital Matrix |
2019-08-05 |
| GNA Biosolutions–Occident: investment, 201908 financing round Series C totalling $13.5m incl new investor Occident |
2019-08-05 |
| GNA Biosolutions–SEVERAL: investment, 201908 financing round Series C $13.5m from new + existing EU + US investors |
2019-08-05 |
| GNA Biosolutions–SHS Capital: investment, 201908 financing round Series C totalling $13.5m incl existing investor SHS |
2019-08-05 |
| GNA Biosolutions–UVC Partners: investment, 201908 financing round Series C totalling $13.5m incl existing investor UVC Partners |
2019-08-05 |
| Inveox–SEVERAL: investment, 201908 3rd financing round €17m |
2019-08-05 |
| Babylon Health–SEVERAL: investment, 201908 financing round $550m from existing + new investors |
2019-08-02 |
| Immunic–Germany (govt): grant, 201908–202207 BMBF grant €654k to support German-Japanese research project with InnoMuNIiCH project |
2019-08-01 |
| Wellington Partners–Consilium: public relations, 201907 service existent by CSC |
2019-07-31 |
| Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF |
2019-07-31 |
| Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital |
2019-07-31 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx |
2019-07-31 |
| Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company |
2019-07-31 |
| Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO |
2019-07-31 |
| Quanta Dialysis Technologies–btov Partners: investment, 201907 financing round Series C totalling £38m incl existing + co-lead investor btov Partners |
2019-07-29 |
| Quanta Dialysis Technologies–OTHER: investment, 201907 financing round Series C totalling £38m incl co-lead investor Swiss family office |
2019-07-29 |
| Quanta Dialysis Technologies–Seroba: investment, 201907 financing round Series C totalling £38m incl existing + co-lead investor Seroba Life Sciences |
2019-07-29 |
| Quanta Dialysis Technologies–SEVERAL: investment, 201907 financing round Series C £38m led by Swiss family office + btov Partners |
2019-07-29 |
| Quanta Dialysis Technologies–Wellington Partners: investment, 201907 financing round Series C totalling £38m incl existing + co-lead investor WP |
2019-07-29 |
| 908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al |
2019-07-25 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| Merck (DE)–908 Devices: biopharma production technology, 201907– collab 908 + MilliporeSigma + Univ North Carolina on bioreactor process analytics |
2019-07-25 |
| EverlyWell–PerkinElmer: consumer diagnostics, 201907– collab + supply CAP lab services immunoassays + genomic tests for US home health test market |
2019-07-24 |
| Freenome–Roche: investment, 201907 financing round Series B totalling $160m incl new + co-investor Roche Venture Fund |
2019-07-24 |
| Freenome–SEVERAL: investment, 201907 financing round Series B $160m co-led by RA Capital Management + Polaris Partners + incl Roche Venture Fund |
2019-07-24 |
| Gilead–Novartis: virostatic agents, 201907– license excl ww for three preclinical antivirals incl upfront payment plus $291m milestones + royalties |
2019-07-19 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Boehringer–Bridge Biotherapeutics: autotaxin inhibitor, 201907– collab + ww license BBT-877 up to €45m upfront/near-term + up to €1.1b + royalties |
2019-07-18 |
| MIT–Merck (DE): CRISPR technology, 201907– collab pooling of IP from Merck + Broad Institute for licensing CRISPR for RnD by Broad |
2019-07-18 |
| Pyxis Oncology–Agent Capital: investment, 201907 financing round Series A totalling $22m incl co-investor Agent Capital |
2019-07-17 |
| Pyxis Oncology–Bayer: investment, 201907 financing round Series A totalling $22m incl lead investor Leaps by Bayer |
2019-07-17 |
| Pyxis Oncology–Ipsen: investment, 201907 financing round Series A totalling $22m incl co-investor Ipsen |
2019-07-17 |
| Pyxis Oncology–Longwood Fund: investment, 201907 financing round Series A totalling $22m incl co-investor Longwood Fund |
2019-07-17 |
| Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer |
2019-07-17 |
| AM-Pharma–Eurazeo: investment, 201907 financing round totalling €116m incl existing + co-investor Kurma Partners |
2019-07-16 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| Bayer–Evogene: plant genomics, 201907 collaboration amendment to refocus on genome editing target discovery for corn diseases |
2019-07-16 |
| Roche–Sosei: GPCR-targeting drugs, 201907– collab multi-target research + licensing up to >$1b Genentech + Sosei Heptares |
2019-07-16 |
| Amal Therapeutics–Boehringer: investment, 201907 acquisition of Amal by Boehringer for up to €325m |
2019-07-15 |
| Ncardia–Evotec: investment, 201907 acquisition €na of iPSC assets + 17 strong team of bankrupt Ncardia AG in Cologne |
2019-07-15 |
| Vasopharm–Bavaria (govt): investment, 201907 financing round totalling €9.5m incl existing + co-investor Bayern Kapital |
2019-07-11 |
| Vasopharm–Creathor Ventures: investment, 201907 financing round totalling €9.5m incl new + co-investor Creathor Ventures |
2019-07-11 |
| Vasopharm–EF Investments: investment, 201907 financing round totalling €9.5m incl co-lead investor EF Investments |
2019-07-11 |
| Vasopharm–HeidelbergCapital: investment, 201907 financing round totalling €9.5m incl existing + co-lead investor HeidelbergCapital Private Equity |
2019-07-11 |
| Vasopharm–Hessen (govt): investment, 201907 financing round totalling €9.5m incl existing + co-investor Future Capital |
2019-07-11 |
| Vasopharm–Optimum Strategic Communications: public relations, 201907 service existent by Optimum |
2019-07-11 |
| Vasopharm–SEVERAL: investment, 201907 financing round €9.5m co-led by HeidelbergCapital Private Equity + EF Investments |
2019-07-11 |
| BioNTech–BVCF Management: investment, 201907 financing round Series B totalling $325m incl co-investor BVCF Management |
2019-07-09 |
| BioNTech–Fidelity: investment, 201907 financing round Series B totalling $325m incl existing + lead investor Fidelity Management and Research |
2019-07-09 |
| BioNTech–Invus Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Invus |
2019-07-09 |
| BioNTech–Jebsen Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Jebsen Capital |
2019-07-09 |
| BioNTech–Mirae Asset: investment, 201907 financing round Series B totalling $325m incl co-investor Mirae Asset Financial Group |
2019-07-09 |
| BioNTech–Platinum Asset Management: investment, 201907 financing round Series B totalling $325m incl co-investor Platinum Asset Management |
2019-07-09 |
| BioNTech–Redmile Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Redmile Group |
2019-07-09 |
| BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by Fidelity ./. €87.7m delayed as of 9/19 |
2019-07-09 |
| BioNTech–Steam Athena Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Steam Athena Capital |
2019-07-09 |
| BioNTech–Strüngmann Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investorStrüngmann Family Office |
2019-07-09 |
| Revolution Medicines–Nextech: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Nextech Invest |
2019-07-09 |
| Breakpoint Therapeutics–Evotec: investment, 201907 first financing round totalling €30m incl co-investor Evotec |
2019-07-08 |
| Breakpoint Therapeutics–Medicxi Ventures: investment, 201907 first financing round totalling €30m incl lead investor Medicxi |
2019-07-08 |
| Breakpoint Therapeutics–Otsuka: investment, 201907 first financing round totalling €30m incl co-investor Taiho Ventures LLC |
2019-07-08 |
| Breakpoint Therapeutics–SEVERAL: investment, 201907 first financing round €30m for spin-out from Evotec led by Medicxi + incl Taiho Ventures + Evotec |
2019-07-08 |
| PMOD Technologies–Bruker: investment, 201907 acquisition €na of PMOD Technologies LLC by Bruker |
2019-07-08 |
| Nosopharm–Evotec: antibiotics, 201907– collab €na pre-clinical developm of NOSO-502 + 2nd generation odilorhabdin |
2019-07-03 |
| Pantherna Therapeutics–Brandenburg (govt): investment, 201907 seed financing round totalling €3.5m incl investor State of Brandenburg |
2019-07-03 |
| Pantherna Therapeutics–EU (govt): investment, 201907 seed financing round totalling €3.5m incl investor European Investment Fund |
2019-07-03 |
| Pantherna Therapeutics–High-Tech Gründerfonds: investment, 201907 seed financing round totalling €3.5m incl investor HTGF |
2019-07-03 |
| Pantherna Therapeutics–PERSON: investment, 201907 seed financing round totalling €3.5m incl investor Detlev Riesner |
2019-07-03 |
| Pantherna Therapeutics–SEVERAL: investment, 201907 seed financing round €3.5m from HTGF + Detlev Riesner + EIF + State of Brandenburg |
2019-07-03 |
| Boehringer–Yuhan: GLP1R/FGF21R agonist, 201907– collab + license agreem for FGF21 $40m upfront + $830m milestones + royalties |
2019-07-01 |
| Century Therapeutics–Bayer: investment, 201907 financing round totalling $250m commitments incl $215m from Leaps by Bayer |
2019-07-01 |
| Century Therapeutics–Fujifilm: investment, 201907 financing round totalling $250m commitments incl co-investor Fujifilm Cellular Dynamics Inc |
2019-07-01 |
| Century Therapeutics–SEVERAL: investment, 201907 financing round $250m commitments from Leaps by Bayer + Versant Ventures + Fujifilm CDI |
2019-07-01 |
| Century Therapeutics–Versant Ventures: investment, 201907 financing round totalling $250m commitments incl existing + co-investor Versant Ventures |
2019-07-01 |
| ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics |
2019-07-01 |
| Merck (DE)–SEVERAL: credit, 201907 three bonds amounting to €2b to finance acquisition of Versum Materials Inc |
2019-07-01 |
| Resistell–Switzerland (govt): grant, 201907c Innosuisse Innovation funding CHF1.3m for project of Resistell + CHUV |
2019-07-01 |
| CryoTherapeutics–SEVERAL: investment, 201906 financing round Series B €7m incl equity + debt + non-dilutive cash advances |
2019-06-27 |
| Modag–Massa Investment: investment, 201906 financing round Series A totalling €12m incl lead investor Massa Investment AG |
2019-06-27 |
| Modag–SEVERAL: investment, 201906 financing round Series A €12m led by Massa Investment AG |
2019-06-27 |
| Modag–Trophic Communications: public relations, 201906 service existent by Trophic |
2019-06-27 |
| PhagoMed–SEVERAL: investment, 201906 2nd financing round €1.5m from existing + new investors |
2019-06-27 |
| Velabs Therapeutics–SEVERAL: investment, 201906 financing round Series B €3m |
2019-06-27 |
| Evotec–SEVERAL: credit, 201906– promissory note €250m with lead arrangers Deutsche Bank + LBBW |
2019-06-26 |
| Allergan–AbbVie: investment, 201905– acquisition $63b in cash + shares by AbbVie ANNOUNCED |
2019-06-25 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| Avacta–JSR Corp: cell line development, 201906– CHO cell line development for clinical manufacturing of AVA004 Affimer PD-L1 antagonist by Selexis |
2019-06-20 |
| Gamida Cell–Lonza: cell therapy contract manufacturing, 201906– supply multi-year future commercial production of omidubicel by Lonza in Geleen (NL) |
2019-06-19 |
| Germany (govt)–Trophic Communications: public relations, 201906 service existent for German Accelerator Life Sciences by Trophic |
2019-06-18 |
| Merck (DE)–SEVERAL: credit, 201906 hybrid €1.5b bond to finance acquisition of Versum Materials Inc |
2019-06-18 |
| Osteolabs–MVZ Dr Krause: investment, 201906 seed financing round incl investor MVZ Dr Krause und Kollegen Kiel |
2019-06-17 |
| Osteolabs–OTHER: investment, 201906 seed financing round incl two business angel investors |
2019-06-17 |
| Osteolabs–Schleswig-Holstein (govt): investment, 201906 seed financing round incl investor MGB Kiel Seed und Start-Up Fonds II |
2019-06-17 |
| Osteolabs–SEVERAL: investment, 201906 seed financing round from MGB Kiel + MVZ Dr Krause Kiel + two business angels |
2019-06-17 |
| Freeline Therapeutics–Egon Zehnder: recruitment services, 201906– supply service executive search for CEO position |
2019-06-13 |
| ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m |
2019-06-12 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 33 34 35 ... 38 39 40 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
